Gadofosveset trisodium

Identification

Summary

Gadofosveset trisodium is an intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.

Brand Names
Vasovist
Generic Name
Gadofosveset trisodium
DrugBank Accession Number
DB06705
Background

Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1003.85
Monoisotopic: 1004.081
Chemical Formula
C33H38GdN3Na5O14P
Synonyms
  • Gadofosveset
External IDs
  • MS-325

Pharmacology

Indication

Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum albumin.

Mechanism of action

Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood.

Absorption

Not Available

Volume of distribution

48 ± 16 mL/kg

Protein binding

80-90%

Metabolism

Gadofosveset does not undergo measurable metabolism.

Route of elimination

Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%).

Half-life

18.5 hours

Clearance

6.57 ± 0.97 mL/h/kg following the administration of 0.03 mmol/kg.

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²).

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
AclidiniumGadofosveset trisodium may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineGadofosveset trisodium may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Gadofosveset trisodium monohydrateXM33Q67UVH211570-55-7PIZALBORPSCYJU-QSQMUHTISA-H
Active Moieties
NameKindUNIICASInChI Key
Gadolinium cation (3+)ionicAZV954TZ9N22541-19-1RJOJUSXNYCILHH-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution244 mg/1mLIntravenousLantheus Medical Imaging2008-12-122016-09-01US flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarSolution244 mg / mLIntravenousLantheus Mi Canada Inc2010-10-122016-03-07Canada flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag
AblavarInjection, solution0.25 mmol/mlIntravenousTmc Pharma Services Ltd.2016-09-202011-11-14EU flag

Categories

ATC Codes
V08CA11 — Gadofosveset
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
9430ZR8ZAN
CAS number
193901-90-5
InChI Key
XGOSYNSWSRUASG-SSMZTGFVSA-H
InChI
InChI=1S/C33H44N3O14P.Gd.3Na/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;/q;+3;3*+1/p-6/t26-;;;;/m1..../s1
IUPAC Name
SMILES
[Na+].[Na+].[Na+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)C[C@H](COP([O-])(=O)OC1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1)N(CC([O-])=O)CC([O-])=O

References

General References
  1. Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA: 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013 Jun;29(5):1085-94. doi: 10.1007/s10554-013-0192-z. Epub 2013 Mar 21. [Article]
  2. Hrdina L, Kocher M, Herman M, Cerna M, Kozak J, Tudos Z, Mahathmakanthi S, Langova K: Comparison of the quality of lower limb magnetic resonance angiographies performed with different paramagnetic contrast agents in relation to body mass index and ejection fraction. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Jun;156(2):164-70. doi: 10.5507/bp.2011.058. [Article]
  3. Thouet T, Schnackenburg B, Kokocinski T, Fleck E, Nagel E, Kelle S: Visualization of chronic myocardial infarction using the intravascular contrast agent MS-325 (gadofosveset) in patients. ScientificWorldJournal. 2012;2012:236401. doi: 10.1100/2012/236401. Epub 2012 Mar 12. [Article]
  4. Milot L, Haider M, Foster L, McGregor C, Law C: Gadofosveset trisodium in the investigation of focal liver lesions in noncirrhotic liver: Early experience. J Magn Reson Imaging. 2012 Sep;36(3):738-42. doi: 10.1002/jmri.23650. Epub 2012 Apr 5. [Article]
  5. Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p. [Article]
  6. FDA Approved Drug Products: ABLAVAR (gadofosveset trisodium) injection [Link]
KEGG Drug
D04286
PubChem Compound
73049652
PubChem Substance
175427086
ChemSpider
9847191
RxNav
1364289
ChEMBL
CHEMBL1908362
PharmGKB
PA165958378
Drugs.com
Drugs.com Drug Page
Wikipedia
Gadofosveset
FDA label
Download (148 KB)
MSDS
Download (66.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticChronic Liver Diseases (CLD)1
4RecruitingDiagnosticPediatric Congenital Heart Disease1
4Unknown StatusDiagnosticCongenital Heart Disease (CHD)1
4WithdrawnDiagnosticNeoplasms, Ovarian1
3CompletedDiagnosticPeripheral Vascular Disease Patient1
3CompletedDiagnosticSteno-Occlusive Disease1
2CompletedDiagnosticMalignancies1
2CompletedDiagnosticMyocardial Ischemia1
1CompletedDiagnosticAtherosclerosis / Chronic Total Aterial Occlusion / Intermittent Claudication / Peripheral Arterial Disease (PAD)1
Not AvailableCompletedNot AvailableMagnetic Resonance Imaging (MRI) / Neoplasms Staging / Rectal Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous0.25 mmol/ml
Injection, solutionIntravenous244 mg/1mL
InjectionIntravenous244 mg/1mL
Injection, solutionIntravenous
SolutionIntravenous244 mg / mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA2304461No2008-10-142018-08-17Canada flag
CA2211100No2007-03-202016-01-16Canada flag
US6676929No2004-01-132020-05-04US flag

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.169 mg/mLALOGPS
logP3.84ALOGPS
logS-3.8ALOGPS
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.8572
Blood Brain Barrier+0.6355
Caco-2 permeable-0.5948
P-glycoprotein substrateSubstrate0.6107
P-glycoprotein inhibitor IInhibitor0.6422
P-glycoprotein inhibitor IINon-inhibitor0.6901
Renal organic cation transporterNon-inhibitor0.6739
CYP450 2C9 substrateNon-substrate0.7903
CYP450 2D6 substrateNon-substrate0.8158
CYP450 3A4 substrateNon-substrate0.5501
CYP450 1A2 substrateNon-inhibitor0.7768
CYP450 2C9 inhibitorNon-inhibitor0.7121
CYP450 2D6 inhibitorNon-inhibitor0.8278
CYP450 2C19 inhibitorNon-inhibitor0.6916
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8798
Ames testNon AMES toxic0.6081
CarcinogenicityNon-carcinogens0.7542
BiodegradationNot ready biodegradable0.9604
Rat acute toxicity2.6392 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5557
hERG inhibition (predictor II)Non-inhibitor0.5302
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Meaney JF, Goyen M: Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol. 2007 Mar;17 Suppl 2:B2-6. [Article]
  2. Caravan P: Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res. 2009 Jul 21;42(7):851-62. doi: 10.1021/ar800220p. [Article]
  3. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ: Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem. 2007 Aug 6;46(16):6632-9. Epub 2007 Jul 11. [Article]
  4. Henness S, Keating GM: Gadofosveset. Drugs. 2006;66(6):851-7. [Article]

Drug created on May 16, 2010 00:37 / Updated on September 09, 2021 09:05